Fylde Clinic Mounjaro cost considerations are essential for patients exploring private tirzepatide treatment in the UK. Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes and weight management, typically costs £150–£300 monthly through private clinics, with additional consultation and monitoring fees. Understanding the full financial commitment—including initial assessments, follow-up appointments, dose escalation protocols, and ongoing clinical oversight—enables informed decision-making. This article examines pricing structures at private clinics, compares NHS versus private access, and explains factors influencing Mounjaro costs across UK healthcare providers.

Mounjaro Cost at Fylde Clinic: What to Expect

When considering Mounjaro (tirzepatide) treatment at Fylde Clinic or similar private healthcare providers in the UK, patients should anticipate costs that reflect both the medication itself and associated clinical services. Private prescription costs for Mounjaro typically range from £150 to £300 per month for the medication alone, with substantial variation depending on the prescribed dose (higher doses such as 10-15mg costing significantly more) and clinic pricing structure.

At private clinics, the total cost encompasses several components beyond the medication. Initial consultation fees generally range from £50 to £150, during which a clinician assesses your suitability for treatment, reviews your medical history, and discusses potential risks and benefits. Follow-up appointments, which are essential for monitoring progress and adjusting dosages, may cost between £30 and £100 per session. Many clinics offer package deals that bundle consultations with medication supply, potentially offering better value for patients committed to long-term treatment.

It is important to note that Mounjaro requires a gradual dose escalation protocol, starting at 2.5 mg weekly and potentially increasing to maintenance doses of 5 mg, 10 mg, or 15 mg depending on individual response and tolerability. Higher doses naturally incur greater costs. Patients should budget for a minimum commitment of three to six months to assess treatment efficacy properly, as weight loss and metabolic improvements occur progressively.

Before committing to private treatment, prospective patients should request a detailed breakdown of all costs, including any additional charges for blood tests, monitoring of weight/BMI, blood pressure, and relevant blood tests based on clinical judgement. Additional practical considerations include refrigerated storage requirements before first use, sharps disposal arrangements, and injection training. Due to ongoing supply constraints affecting GLP-1/GIP medications, patients should confirm availability before committing to treatment.

NHS vs Private Mounjaro Prescriptions in the UK

The availability of Mounjaro through the NHS versus private healthcare represents a significant consideration for patients seeking this treatment. NICE has recommended tirzepatide for weight management under specific criteria via specialist weight management services, though implementation varies across the UK. For type 2 diabetes, NICE guidance also recommends tirzepatide in defined clinical circumstances.

For NHS eligibility where available, patients typically must meet specific criteria: generally a body mass index (BMI) of 35 kg/m² or above with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea), or a BMI of 30 kg/m² or above in certain circumstances. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, BMI thresholds are reduced by 2.5 kg/m². Even when criteria are met, access varies considerably across different Integrated Care Boards (ICBs), with some areas having limited provision whilst others may have established specialist weight management services.

Private prescriptions offer immediate access without lengthy waiting lists, provided patients meet clinical safety criteria. Private clinics can prescribe Mounjaro in line with its licensed indication for weight management (BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to reduced-calorie diet and increased physical activity. However, this convenience comes at substantial personal expense, with annual costs potentially exceeding £2,000 to £3,000 when including consultations and monitoring.

Patients should be aware that continuation of privately-initiated treatment by the NHS is not guaranteed and depends on local ICB policies and shared-care arrangements. Patients should check local policies before commencing private treatment. Some private health insurance policies may cover consultations but typically exclude weight management medications, making out-of-pocket payment the norm.

Factors Affecting Mounjaro Pricing at Private Clinics

Several variables influence the cost of Mounjaro treatment at private clinics across the UK, creating price variations between providers. Understanding these factors helps patients make informed decisions and identify clinics offering fair value.

Medication sourcing and supply chain costs represent the primary expense. Clinics that purchase Mounjaro directly from licensed UK wholesalers or pharmacy partners face different pricing structures than those using alternative supply arrangements. The ongoing global demand for GLP-1 receptor agonists has created supply constraints, which can affect pricing and availability. Reputable clinics should only dispense medication obtained through legitimate UK-licensed channels, ensuring product authenticity and patient safety.

Clinical service models significantly impact overall costs. Some clinics provide minimal clinical oversight, whilst others offer comprehensive weight management programmes including dietetic support, exercise guidance, and regular monitoring. Whilst the latter approach costs more initially, it aligns with best practice guidelines and may improve treatment outcomes. All prescribers must follow GMC good practice in prescribing (including for remote consultations), and medicines should be dispensed via registered UK pharmacies. Services providing treatment for medical conditions should be appropriately regulated, including CQC registration where applicable.

Geographical location influences pricing, with London and South East clinics generally charging premium rates compared to providers in other UK regions. However, the rise of telemedicine services has somewhat equalised access, allowing patients to consult with clinics nationwide whilst receiving prescriptions at their local pharmacy.

Dose escalation schedules affect monthly costs, as patients progress from starter doses (2.5 mg) to maintenance doses (5–15 mg). Clinics offering flexible dosing based on individual response rather than rigid protocols may provide better value. Patients should also enquire about policies regarding dose adjustments, treatment pauses, or discontinuation—transparent terms protect against unexpected costs.

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a novel medication licensed in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of type 2 diabetes mellitus and for chronic weight management in adults with obesity or overweight with weight-related comorbidities. It is specifically indicated as an adjunct to reduced-calorie diet and increased physical activity for weight management in adults with an initial BMI of ≥30 kg/m², or ≥27 kg/m² in the presence of at least one weight-related comorbidity.

Pharmacologically, tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This means it simultaneously activates two incretin hormone pathways that naturally regulate glucose metabolism and appetite. The GLP-1 component enhances insulin secretion when blood glucose is elevated, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite through central nervous system effects. The GIP component complements these actions by improving insulin sensitivity and may have additional beneficial effects on fat metabolism. This dual action produces more pronounced effects on weight loss and glycaemic control than single-pathway GLP-1 agonists like semaglutide.

Administered as a once-weekly subcutaneous injection using a pre-filled pen device, Mounjaro offers convenience compared to daily medications. The injection is typically given in the abdomen, thigh, or upper arm, with patients rotating sites to minimise injection-site reactions. Treatment begins at 2.5 mg weekly for four weeks, then escalates to 5 mg. Further increases to 7.5 mg, 10 mg, 12.5 mg, or 15 mg may occur at four-week intervals based on individual response and tolerability.

Common adverse effects include gastrointestinal symptoms—nausea, diarrhoea, vomiting, constipation, and abdominal discomfort—which typically diminish over time as the body adapts. These effects are generally mild to moderate and can be minimised through gradual dose escalation and dietary modifications. Serious but rare adverse effects include pancreatitis and gallbladder disease. Tirzepatide is not indicated for type 1 diabetes and is not recommended during pregnancy or breastfeeding. In patients with diabetic retinopathy, particularly those with type 2 diabetes experiencing rapid improvement in glucose control, appropriate monitoring should be considered. Patients should stop treatment and seek urgent medical advice if pancreatitis is suspected (persistent, severe abdominal pain). The medicine should be stored in a refrigerator before first use (do not freeze) and patients should be advised to report any suspected side effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions